The onset of ulcerative colitis during treatment with secukinumab: can anti-IL-17A be a trigger for inflammatory bowel disease?

Rodríguez Moncada, RafaelVázquez Morón, Juan MaríaPallarés Manrique, Héctor2023-01-252023-01-2520191130-0108http://hdl.handle.net/10668/14284In recent months, cases of IBD have been reported in the context of treatment with secukinumab, a monoclonal antibody that blocks IL-17A and which is used in the treatment of certain rheumatic disorders. We present a case of a patient with psoriatic arthritis, with a first-degree relative who had suffered ulcerative colitis, who presented with onset ulcerative colitis in the weeks following treatment initiation with this drug.enAdultAntibodies, Monoclonal, HumanizedArthritis, PsoriaticColitis, UlcerativeDiarrheaGastrointestinal HemorrhageHumansInterleukin-17MaleRectumThe onset of ulcerative colitis during treatment with secukinumab: can anti-IL-17A be a trigger for inflammatory bowel disease?research article31333036open access10.17235/reed.2019.5841/2018https://doi.org/10.17235/reed.2019.5841/2018